PREVIEW

Bayer Offers $7.25bn To Settle Roundup Cancer Claims. Bayer has proposed a $7.25 billion settlement to resolve ongoing US legal claims linking its Roundup weedkiller to cancer. The move forms part of a broader effort to bring closure to years of litigation that have weighed heavily on the company since it acquired Monsanto for $63 billion. Bayer has already paid around $10 billion to settle previous claims but continues to face thousands more. The latest proposal would apply to cases involving non-Hodgkin lymphoma, a form of blood cancer. Chief executive Bill Anderson says the deal is designed to achieve finality, stressing that it only works if it delivers lasting closure. The settlement would still require court approval. Roundup’s key ingredient, glyphosate, was classified in 2015 as a probable carcinogen by the International Agency for Research on Cancer, a branch of the World Health Organization. Bayer and the US Environmental Protection Agency dispute that assessment. While more than 130,000 claims have been resolved, around 65,000 remain outstanding.
Instructions: THIS VIDEO MUST NOT BE EDITED FOR LENGTH TO COMBINE WITH OTHER CONTENT